drugset / Trial / NCT00802360

MENOPUR® Versus FOLLISTIM®

NCT00802360

Phase 4 Completed 173 enrolled Ferring Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

To compare the efficacy and safety of highly purified menotropin (Menopur®) with that of follitropin beta (FOLLISTIM®) in patients who are undergoing gonadotropin-releasing hormone (GnRH) antagonist in vitro fertilization (IVF) cycles

Timeline

Start
2008-12
Primary completion
2009-11
Completion
2010-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Follitropin beta Protein / enzyme biologic 225 iu Subcutaneous
Subject Menopur Protein / enzyme biologic 225 iu Subcutaneous
Subject Progesterone Other / unclassified 50 mg Other
Subject Progesterone Other / unclassified 100 mg Other
Background Ganirelix Protein / enzyme biologic 250 ug Subcutaneous

Indications